Literature DB >> 7790090

Human peripheral blood CD4+ and CD8+ T cells express Th1-like cytokine mRNA and proteins following in vitro stimulation with heat-inactivated Brucella abortus.

M B Zaitseva1, H Golding, M Betts, A Yamauchi, E T Bloom, L E Butler, L Stevan, B Golding.   

Abstract

Defining the pattern of lymphokine production associated with Brucella abortus is critical for advancing the development of B. abortus as a vaccine carrier. In the present study we investigated the ability of heat-inactivated B. abortus or lipopolysaccharide from B. abortus to induce lymphokine production from purified human T cells in vitro. Gamma interferon (IFN-gamma), interleukin-2 (IL-2), IL-4, and IL-5 induction was assayed by mRNA-specific PCR and by enzyme-linked immunosorbent assay and bioassay for protein production. Following depletion of monocytes and B cells, B. abortus increased IFN-gamma and IL-2 mRNA expression in purified T cells compared with expression in unstimulated cells. In contrast, no IL-5 mRNA expression and only transient low-level IL-4 mRNA expression and no IL-4 protein secretion were detected. Phytohemagglutinin or phorbol myristate acetate plus ionomycin induced mRNA and protein for all these cytokines. Similar results were obtained with LPS purified from B. abortus. Removal of NK cells did not reduce lymphokine production, and enriched NK cells did not express IFN-gamma mRNA or secrete IFN-gamma protein in response to B. abortus, indicating that NK cells were not the responding population. Both CD4+ and CD8+ populations produced IFN-gamma and IL-2 in response to B. abortus. Preincubation of resting T cells with B. abortus or LPS from B. abortus for 7 days induced their differentiation into Th1-like cells as judged by their subsequent lymphokine response to phorbol myristate acetate plus ionomycin. These results suggest that B. abortus can induce differentiation of Th0 into Th1-type cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7790090      PMCID: PMC173364          DOI: 10.1128/iai.63.7.2720-2728.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  50 in total

1.  Anti-CD3 antibody induces rapid expression of cytokine genes in vivo.

Authors:  D E Scott; W C Gause; F D Finkelman; A D Steinberg
Journal:  J Immunol       Date:  1990-10-01       Impact factor: 5.422

2.  IFN-gamma- and IL-5-producing cells compartmentalize to different lymphoid organs in Trichinella spiralis-infected mice.

Authors:  E A Kelly; E S Cruz; K M Hauda; D L Wassom
Journal:  J Immunol       Date:  1991-07-01       Impact factor: 5.422

3.  Ablation of eosinophil and IgE responses with anti-IL-5 or anti-IL-4 antibodies fails to affect immunity against Schistosoma mansoni in the mouse.

Authors:  A Sher; R L Coffman; S Hieny; A W Cheever
Journal:  J Immunol       Date:  1990-12-01       Impact factor: 5.422

4.  Cytotoxic T lymphocyte control of acute lymphocytic choriomeningitis virus infection: interferon gamma, but not tumour necrosis factor alpha, displays antiviral activity in vivo.

Authors:  L S Klavinskis; R Geckeler; M B Oldstone
Journal:  J Gen Virol       Date:  1989-12       Impact factor: 3.891

5.  Mechanism of inhibition of HSV-1 replication by tumor necrosis factor and interferon gamma.

Authors:  E Feduchi; L Carrasco
Journal:  Virology       Date:  1991-02       Impact factor: 3.616

6.  Cellular and molecular mechanisms for reduced interleukin 4 and interferon-gamma production by neonatal T cells.

Authors:  D B Lewis; C C Yu; J Meyer; B K English; S J Kahn; C B Wilson
Journal:  J Clin Invest       Date:  1991-01       Impact factor: 14.808

7.  Allergen- and bacterial antigen-specific T-cell clones established from atopic donors show a different profile of cytokine production.

Authors:  P Parronchi; D Macchia; M P Piccinni; P Biswas; C Simonelli; E Maggi; M Ricci; A A Ansari; S Romagnani
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

8.  Egg deposition is the major stimulus for the production of Th2 cytokines in murine schistosomiasis mansoni.

Authors:  J M Grzych; E Pearce; A Cheever; Z A Caulada; P Caspar; S Heiny; F Lewis; A Sher
Journal:  J Immunol       Date:  1991-02-15       Impact factor: 5.422

9.  Brucella abortus conjugated with a gp120 or V3 loop peptide derived from human immunodeficiency virus (HIV) type 1 induces neutralizing anti-HIV antibodies, and the V3-B. abortus conjugate is effective even after CD4+ T-cell depletion.

Authors:  B Golding; J Inman; P Highet; R Blackburn; J Manischewitz; N Blyveis; R D Angus; H Golding
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

10.  Differentiation of T cell lymphokine gene expression: the in vitro acquisition of T cell memory.

Authors:  S Ehlers; K A Smith
Journal:  J Exp Med       Date:  1991-01-01       Impact factor: 14.307

View more
  21 in total

1.  Down-regulation of Th2 responses by Brucella abortus, a strong Th1 stimulus, correlates with alterations in the B7.2-CD28 pathway.

Authors:  I Agranovich; D E Scott; D Terle; K Lee; B Golding
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

2.  Brucella abortus conjugated with a peptide derived from the V3 loop of human immunodeficiency virus (HIV) type 1 induces HIV-specific cytotoxic T-cell responses in normal and in CD4+ cell-depleted BALB/c mice.

Authors:  C Lapham; B Golding; J Inman; R Blackburn; J Manischewitz; P Highet; H Golding
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

Review 3.  Pathogenesis and immunobiology of brucellosis: review of Brucella-host interactions.

Authors:  Paul de Figueiredo; Thomas A Ficht; Allison Rice-Ficht; Carlos A Rossetti; L Garry Adams
Journal:  Am J Pathol       Date:  2015-04-17       Impact factor: 4.307

4.  Mouse cytokine profiles associated with Brucella abortus RB51 vaccination or B. abortus 2308 infection.

Authors:  P Pasquali; R Adone; L C Gasbarre; C Pistoia; F Ciuchini
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

5.  Induction of antigen-specific Th1-type immune responses by gamma-irradiated recombinant Brucella abortus RB51.

Authors:  Neelima Sanakkayala; Anna Sokolovska; Jatinder Gulani; Harm Hogenesch; Nammalwar Sriranganathan; Stephen M Boyle; Gerhardt G Schurig; Ramesh Vemulapalli
Journal:  Clin Diagn Lab Immunol       Date:  2005-12

6.  Infection outcome and cytokine gene expression in Brugia pahangi- infected gerbils (Meriones unguiculatus) sensitized with Brucella abortus.

Authors:  Sharon R Chirgwin; Philip H Elzer; Sharon U Coleman; Jena M Nowling; Sue D Hagius; Matthew D Edmonds; Thomas R Klei
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

7.  CCR8 on human thymocytes functions as a human immunodeficiency virus type 1 coreceptor.

Authors:  S Lee; H L Tiffany; L King; P M Murphy; H Golding; M B Zaitseva
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

8.  Recombinant Ochrobactrum anthropi expressing Brucella abortus Cu,Zn superoxide dismutase protects mice against B. abortus infection only after switching of immune responses to Th1 type.

Authors:  Yongqun He; Ramesh Vemulapalli; Gerhardt G Schurig
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

9.  Brucella abortus as a potential vaccine candidate: induction of interleukin-12 secretion and enhanced B7.1 and B7.2 and intercellular adhesion molecule 1 surface expression in elutriated human monocytes stimulated by heat-inactivated B. abortus.

Authors:  M Zaitseva; H Golding; J Manischewitz; D Webb; B Golding
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

10.  Use of S-[2,3-bispalmitoyiloxy-(2R)-propyl]-R-cysteinyl-amido-monomethoxy polyethylene glycol as an adjuvant improved protective immunity associated with a DNA vaccine encoding Cu,Zn superoxide dismutase of Brucella abortus in mice.

Authors:  Angello Retamal-Díaz; Roberto Riquelme-Neira; Darwin Sáez; Alejandra Rivera; Pablo Fernández; Alex Cabrera; Carlos A Guzmán; Angel Oñate
Journal:  Clin Vaccine Immunol       Date:  2014-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.